Galimedix Therapeutics Completes Single Ascending Dose Part of Phase 1 Study with Oral Mmall Molecule, GAL-101, an Amyloid Beta Aggregation Modulator

Written by Kirsten Ruehl on 6th May 2025. Posted in Client News.